‘Longing’ for the Next Generation of Liquid Biopsy: The Diagnostic Potential of Long Cell-Free DNA in Oncology and Prenatal Testing
AbstractLiquid biopsy using cell-free DNA (cfDNA) has gained global interest as a molecular diagnostic tool. However, the analysis of cfDNA in cancer patients and pregnant women has been focused on short DNA molecules (e.g., ≤ 600 bp). With the detection of long cfDNA in the plasma of pregnant women and cancer patients in two recent studies, a new avenue of long cfDNA-based liquid biopsy has been opened. In this review, we summarize our current knowledge in this nascent field of long cfDNA analysis, focusing on the f ragmentomic and epigenetic features of long cfDNA. In particular, long-read sequencing enabled single-mo...
Source: Molecular Diagnosis and Therapy - July 20, 2023 Category: Molecular Biology Source Type: research
Development of an Affordable ELISA Targeting the SARS-CoV-2 Nucleocapsid and Its Application to Samples from the Ongoing COVID-19 Epidemic in Ghana
ConclusionThis study developed a low-cost and transferable assay that enables highly sensitive and specific detection of human anti-SARS-CoV-2 IgG antibodies. This assay can be modified to include additional antigens and used for continuous monitoring of sero-exposure to SARS-CoV-2 in West Africa. (Source: Molecular Diagnosis and Therapy)
Source: Molecular Diagnosis and Therapy - July 18, 2023 Category: Molecular Biology Source Type: research
Prognostic and Clinical Significance of Human Leukocyte Antigen Class I Expression in Breast Cancer: A Meta-Analysis
ConclusionThis meta-analysis demonstrated that enhanced HLA class I protein expression is significantly associated with the better DFS of patients with breast cancer, especially TNBC, as well as with ER and PR negativity, HER2 positivity, TNBC, and high Ki-67 indices and nuclear grades. The immune target HLA class I may serve as a prognostic indicator for breast cancer. (Source: Molecular Diagnosis and Therapy)
Source: Molecular Diagnosis and Therapy - July 18, 2023 Category: Molecular Biology Source Type: research
Flotufolastat F 18: Diagnostic First Approval
This article summarizes the milestones in the development of flotufolastat F 18 leading to this first approval. (Source: Molecular Diagnosis and Therapy)
Source: Molecular Diagnosis and Therapy - July 13, 2023 Category: Molecular Biology Source Type: research
Omidubicel: First Approval
This article summarizes the milestones in the development of omidubicel leading to this first approval. (Source: Molecular Diagnosis and Therapy)
Source: Molecular Diagnosis and Therapy - June 24, 2023 Category: Molecular Biology Source Type: research
Role of lncRNAs in Remodeling of the Coronary Artery Plaques in Patients with Atherosclerosis
ConclusionsIn our study, 345 DEGs were found to be statistically significant (p < 0.05; FC> 2) between CAP and IMA. Of these, 65 were lncRNA and 280 were mRNA. Thirty-three lncRNAs were upregulated, while 32 lncRNAs were downregulated. Some of the important mRNAs are SPP1, CYP4B1, CHRDL1, MYOC, and ALKAL2, while some of the lncRNAs are LOC105377123, LINC01857, DIO3OS, LOC101928134, and K CNA3 between CAP and IMA tissue. We also identified genes that correlated with statistically significant lncRNAs. The results of this study are expected to be an important source of data in the development of new genetically bas...
Source: Molecular Diagnosis and Therapy - June 22, 2023 Category: Molecular Biology Source Type: research
Correction: Progress in Clinical Gene Therapy for Cardiac Disorders
(Source: Molecular Diagnosis and Therapy)
Source: Molecular Diagnosis and Therapy - June 10, 2023 Category: Molecular Biology Source Type: research
Flow Cytometry of CD5-Positive Hairy Cell Leukemia
ConclusionHCL is an indolent chronic lymphoproliferative disorder and diagnosis is usually straightforward. However, atypical expression of CD5 renders its differential diagnosis more difficult, but FC is a useful tool that allows an optimal classification of the disease and allows initiation of timely satisfactory therapy. (Source: Molecular Diagnosis and Therapy)
Source: Molecular Diagnosis and Therapy - June 9, 2023 Category: Molecular Biology Source Type: research
Long-Read Nanopore Sequencing of RPGR ORF15 is Enhanced Following DNase I Treatment of MinION Flow Cells
We report the novel finding that long-read nanopore sequencing can read throughRPGR-ORF15, a DNA sequence not captured by short-read next-generation sequencing (NGS), but with a more reduced yield. Use of a flow cell wash kit containing DNase I unblocks the pores, allowing reloading of further library aliquots over a 72-h period, increasing yield. The workflow we describe provides a novel solution to the need for a rapid, robust, scalable, cost-effectiveORF15 screening protocol. (Source: Molecular Diagnosis and Therapy)
Source: Molecular Diagnosis and Therapy - June 7, 2023 Category: Molecular Biology Source Type: research
Recent Advancements in Nanomaterials: A Promising Way to Manage Neurodegenerative Disorders
AbstractNeurodegenerative diseases (NDs) such as dementia, Alzheimer ’s disease, Parkinson’s disease, frontotemporal dementia, and amyotrophic lateral sclerosis are some of the most prevalent disorders currently afflicting healthcare systems. Many of these diseases share similar pathological hallmarks, including elevated oxidative stress, mitochondrial dysfunctio n, protein misfolding, excitotoxicity, and neuroinflammation, all of which contribute to the deterioration of the nervous system’s structure and function. The development of diagnostic and therapeutic materials in the monitoring and treatment of these diseas...
Source: Molecular Diagnosis and Therapy - May 22, 2023 Category: Molecular Biology Source Type: research
Nucleic Acid Quality Assessment is Critical to the Success of the Oncomine Dx Target Test for Lung Cancer
ConclusionsDNA concentration and degree of RNA degradation are key factors determining the success of diagnostic testing by the ODxTT. (Source: Molecular Diagnosis and Therapy)
Source: Molecular Diagnosis and Therapy - May 17, 2023 Category: Molecular Biology Source Type: research
Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor
ConclusionsAn increased frequency of genomic alterations is observed in UBCFGFR. These have been linked to immune checkpoint inhibitor resistance. Clinical trials are needed to evaluate UBCFGFR-based biomarkers prognostic of an immune checkpoint inhibitor response. Only then can we successfully incorporate novel therapeutic strategies into the evolving landscape of UBC treatment. (Source: Molecular Diagnosis and Therapy)
Source: Molecular Diagnosis and Therapy - May 17, 2023 Category: Molecular Biology Source Type: research
Immune Checkpoint Blockade Therapy for Breast Cancer: Lessons from Epithelial –Mesenchymal Transition
AbstractImmune checkpoint blockade therapies have generated efficacious responses in certain tumor types; however, the responses of breast carcinomas have been largely limited. Moreover, the identity of various parameters that can predict responses to immunotherapies, and at the same time, serve as putative biomarkers that can be therapeutically targeted to enhance the effectiveness of immunotherapies for breast cancers, remains to be comprehensively delineated. Activation of epithelial –mesenchymal plasticity in cancer cells, including those of the breast, increases their tumor-initiating potential and promotes their ag...
Source: Molecular Diagnosis and Therapy - May 16, 2023 Category: Molecular Biology Source Type: research
Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy
ConclusionWe found that multiple ctDNA processing and analysis methods consistently identified complex longitudinal patterns of clinically relevant mutations, adding support for expanded clinical trials of this technology in a variety of oncology settings. (Source: Molecular Diagnosis and Therapy)
Source: Molecular Diagnosis and Therapy - April 26, 2023 Category: Molecular Biology Source Type: research
Validation of a Transcriptome-Based Assay for Classifying Cancers of Unknown Primary Origin
DiscussionCombining diagnostic prediction tests (e.g., Tempus TO) with sequencing-based variant reporting (e.g., Tempus xT) may expand therapeutic options for patients with cancers of unknown primary or uncertain histology. (Source: Molecular Diagnosis and Therapy)
Source: Molecular Diagnosis and Therapy - April 26, 2023 Category: Molecular Biology Source Type: research
